BRPI0816881A2 - Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto. - Google Patents

Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.

Info

Publication number: BRPI0816881A2
Authority: BR; Brazil
Prior art keywords: compound; disorders; preparing; methods; pharmaceutical composition
Prior art date: 2007-09-21

Application number

Other languages

English (en)

Inventor

Thomas Daniel Aicher

Steven Armen Boyd

Mark Joseph Chicarelli

Kevin Ronald Condroski

Jay Bradford Fell

John P Fischer

Indrani W Gunawardana

Ronald Jay Hinklin

Ajay Singh

Timothy M Turner

Eli M Wallace

Original Assignee

Array Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-21

Filing date

2008-09-15

Publication date

2015-03-17

2008-09-15 Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc

2015-03-17 Publication of BRPI0816881A2 publication Critical patent/BRPI0816881A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BRPI0816881 2007-09-21 2008-09-15 Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto. BRPI0816881A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97422507P	2007-09-21	2007-09-21
PCT/US2008/076401 WO2009042435A1 (en)	2007-09-21	2008-09-15	Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus

Publications (1)

Publication Number	Publication Date
BRPI0816881A2 true BRPI0816881A2 (pt)	2015-03-17

Family

ID=40250949

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0816881 BRPI0816881A2 (pt)	2007-09-21	2008-09-15	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.

Country Status (28)

Country	Link
US (3)	US8212045B2 (pt)
EP (4)	EP2727910B1 (pt)
JP (1)	JP5722037B2 (pt)
KR (1)	KR101566042B1 (pt)
CN (1)	CN101868459B (pt)
AR (1)	AR068628A1 (pt)
AU (1)	AU2008305294B2 (pt)
BR (1)	BRPI0816881A2 (pt)
CA (1)	CA2699718C (pt)
CO (1)	CO6270223A2 (pt)
CR (2)	CR11383A (pt)
DK (1)	DK2209778T3 (pt)
EA (1)	EA019104B1 (pt)
ES (2)	ES2569734T3 (pt)
HR (1)	HRP20120814T1 (pt)
IL (1)	IL204264A (pt)
MA (1)	MA31779B1 (pt)
MX (1)	MX2010002772A (pt)
MY (1)	MY180558A (pt)
NZ (1)	NZ583538A (pt)
PL (1)	PL2209778T3 (pt)
PT (1)	PT2209778E (pt)
SI (1)	SI2209778T1 (pt)
TN (1)	TN2010000100A1 (pt)
TW (1)	TWI423799B (pt)
UA (1)	UA101166C2 (pt)
WO (1)	WO2009042435A1 (pt)
ZA (2)	ZA201002206B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8044041B2 (en) *	2006-11-15	2011-10-25	Forest Laboratories Holdings Limited	Phthalazine derivatives as inhibitors of protein kinase
ES2569734T3 (es)	2007-09-21	2016-05-12	Array Biopharma, Inc.	Derivados de piridin-2-il-tiourea y de piridin-2-il-amina como intermedios para la preparación de piridin-2-il-amino-1,2,4-tiadiazoles activadores de la glucocinasa
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP3199623B1 (en)	2010-03-31	2021-07-28	The Scripps Research Institute	Reprogramming cells
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2609081A1 (en)	2010-08-23	2013-07-03	Amgen Inc.	Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes
CN103391934A (zh)	2011-03-09	2013-11-13	第一三共株式会社	二吡啶基胺衍生物
MX2013011561A (es)	2011-04-05	2014-02-28	Amgen Inc	Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013123444A1 (en)	2012-02-17	2013-08-22	Amgen Inc.	Sulfonyl compounds that interact with glucokinase regulatory protein
WO2013173382A1 (en)	2012-05-15	2013-11-21	Amgen Inc.	Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
IN2014KN02683A (pt) *	2012-05-18	2015-05-08	Amgen Inc
CA2890852A1 (en) *	2012-11-09	2014-05-15	Array Biopharma Inc.	Crystalline forms of (1s)-1-[5-({3-[(2-methylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol
WO2016059647A2 (en) *	2014-10-13	2016-04-21	SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India)	Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1
GB201714777D0 (en)	2017-09-14	2017-11-01	Univ London Queen Mary	Agent
WO2019089478A1 (en)	2017-10-30	2019-05-09	Neuropore Therapies, Inc.	Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
CN114209694A (zh)	2018-05-31	2022-03-22	华领医药技术（上海）有限公司	含有葡萄糖激酶激活剂和ppar受体激活剂的药物组合及其制备方法和用途

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3983246A (en)	1974-04-04	1976-09-28	Fmc Corporation	N-(sulfonyloxy) benzimidoyl halides as bactericidal or fungicidal agents
DE2949913A1 (de) *	1979-12-12	1981-06-25	Basf Ag, 6700 Ludwigshafen	Azofarbstoffe
EP0300688A1 (en)	1987-07-21	1989-01-25	FISONS plc	Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
JPH0228168A (ja) *	1988-04-14	1990-01-30	Sankyo Co Ltd	チアゾール誘導体
US5326776A (en) *	1992-03-02	1994-07-05	Abbott Laboratories	Angiotensin II receptor antagonists
WO1993024442A1 (fr)	1992-05-29	1993-12-09	Yamanouchi Pharmaceutical Co., Ltd.	Medicament renfermant un derive d'acide benzoique, et nouveau derive d'acide benzoique
CA2193725A1 (en)	1994-06-24	1996-01-04	David Cavalla	Aryl derivative compounds and uses to inhibit phosphodiesterase iv acti vity
GB9908410D0 (en) *	1999-04-13	1999-06-09	Pfizer Ltd	Pyridines
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
ID30460A (id)	1999-04-15	2001-12-06	Bristol Myers Squibb Co	Inhibitor-inhibitor protein siklik tirosin kinase
EE200100556A (et)	1999-04-28	2003-02-17	Aventis Pharma Deutschland Gmbh	Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks
IL146582A0 (en)	1999-05-21	2002-07-25	Biovitrum Ab	Novel compounds, their use and preparation
US6465467B1 (en) *	1999-05-21	2002-10-15	Biovitrum Ab	Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
JP4144978B2 (ja)	1999-09-09	2008-09-03	富士フイルム株式会社	１，２，４−チアジアゾール誘導体の合成法
CN1390215A (zh) *	1999-09-10	2003-01-08	麦克公司	酪氨酸激酶抑制剂
US20020065270A1 (en)	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
US6906067B2 (en)	1999-12-28	2005-06-14	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of TNF-α expression
JP2003519143A (ja)	1999-12-28	2003-06-17	ファーマコピーア，インコーポレーティッド	ピリミジン及びトリアジン系キナーゼ阻害剤
US7345051B2 (en)	2000-01-31	2008-03-18	Genaera Corporation	Mucin synthesis inhibitors
US20050209297A1 (en) *	2000-08-31	2005-09-22	Pfizer Inc	Pyrazole derivatives
EP1313710A1 (en)	2000-08-31	2003-05-28	Pfizer Products Inc.	Pyrazole derivatives and their use as protein kinase inhibitors
AU2002213467A1 (en)	2000-10-11	2002-04-22	Chemocentryx, Inc.	Modulation of ccr4 function
US20020132836A1 (en)	2000-10-11	2002-09-19	Chemocentryx Inc.	Compounds and methods for modulating CCR4 function
AU2002239508B9 (en)	2000-12-07	2005-09-08	Gilead Palo Alto, Inc.	Substituted 1, 3, 5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis
WO2002068415A1 (en)	2000-12-21	2002-09-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US20030130264A1 (en) *	2001-02-16	2003-07-10	Tularik Inc.	Methods of using pyrimidine-based antiviral agents
US7144903B2 (en) *	2001-05-23	2006-12-05	Amgen Inc.	CCR4 antagonists
PE20030008A1 (es)	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
EP1397142A4 (en)	2001-06-19	2004-11-03	Bristol Myers Squibb Co	PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
AU2002346053B2 (en) *	2001-06-22	2008-03-13	Merck & Co., Inc.	Tyrosine kinase inhibitors
WO2003059913A1 (en)	2002-01-10	2003-07-24	Bayer Healthcare Ag	Roh-kinase inhibitors
MXPA04007590A (es) *	2002-02-05	2004-12-06	Yamanouchi Pharma Co Ltd	Derivado de 2,4,6-triamino-1,3,5-triacina.
ATE365733T1 (de)	2002-03-15	2007-07-15	Vertex Pharma	Zusammensetzungen brauchbar als protein-kinase- inhibitoren
US7091343B2 (en) *	2002-03-15	2006-08-15	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
US20040009981A1 (en) *	2002-03-15	2004-01-15	David Bebbington	Compositions useful as inhibitors of protein kinases
AU2003225800A1 (en)	2002-03-15	2003-09-29	Hayley Binch	Azolylaminoazine as inhibitors of protein kinases
US8299108B2 (en)	2002-03-29	2012-10-30	Novartis Ag	Substituted benzazoles and methods of their use as inhibitors of raf kinase
ATE447404T1 (de) *	2002-03-29	2009-11-15	Novartis Vaccines & Diagnostic	Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
JPWO2003091213A1 (ja) *	2002-04-25	2005-09-02	アステラス製薬株式会社	新規なアミド誘導体又はその塩
AU2003249369A1 (en) *	2002-06-21	2004-01-06	Cellular Genomics, Inc.	Certain amino-substituted monocycles as kinase modulators
US20040132726A1 (en)	2002-08-09	2004-07-08	Astrazeneca Ab And Nps Pharmaceuticals, Inc.	New compounds
BR0314196A (pt) *	2002-09-10	2005-07-26	Scios Inc	Inibidores de tgf-beta
RU2005113713A (ru)	2002-10-03	2006-01-20	Новартис АГ (CH)	Замещенные (тиазол-2-ил)амиды или сульфонамиды в качестве активаторов глюкокиназы, которые могут применяться при лечении диабета типа 2
JP2006507302A (ja)	2002-10-30	2006-03-02	メルク　エンド　カムパニー　インコーポレーテッド	キナーゼ阻害剤
KR20050101200A (ko)	2003-02-10	2005-10-20	버텍스 파마슈티칼스 인코포레이티드	Ｎ-아릴 카밤산 에스테르를 할로-헤테로아릴과반응시킴으로써 ｎ-헤테로아릴-ｎ-아릴-아민을 제조하는방법 및 유사 방법
WO2004071426A2 (en)	2003-02-11	2004-08-26	Kemia Inc.	Compounds for the treatment of viral infection
WO2004081001A1 (ja)	2003-02-13	2004-09-23	Banyu Pharmaceutical Co., Ltd.	新規２－ピリジンカルボキサミド誘導体
ATE396731T1 (de)	2003-03-25	2008-06-15	Vertex Pharma	Thiazole zur verwendung als inhibitoren von protein-kinasen
US7244763B2 (en) *	2003-04-17	2007-07-17	Warner Lambert Company Llc	Compounds that modulate PPAR activity and methods of preparation
US20070027321A1 (en) *	2003-09-02	2007-02-01	Kamenecka Theodore M	Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
US7470712B2 (en)	2004-01-21	2008-12-30	Bristol-Myers Squibb Company	Amino-benzazoles as P2Y1 receptor inhibitors
WO2005077373A2 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Treatment of gastro-esophageal reflux disease (gerd)
AR049418A1 (es)	2004-02-27	2006-08-02	Bayer Pharmaceuticals Corp	Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
KR20050091462A (ko)	2004-03-12	2005-09-15	한국과학기술연구원	푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
US7687502B2 (en)	2004-03-23	2010-03-30	Banyu Pharmaceutical Co., Ltd.	Substituted quinazoline or pyridopyrimidine derivative
JP2007530631A (ja)	2004-04-02	2007-11-01	ノバルティスアクチエンゲゼルシャフト	チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法
CA2560346A1 (en)	2004-04-13	2005-10-27	Icagen, Inc.	Polycyclic pyridines as potassium ion channel modulators
EP1742935B1 (en)	2004-04-13	2010-02-24	Icagen, Inc.	Polycyclic pyrazines as potassium ion channel modulators
TW200606129A (en) *	2004-07-26	2006-02-16	Chugai Pharmaceutical Co Ltd	Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
WO2006071095A1 (en)	2004-12-31	2006-07-06	Sk Chemicals Co., Ltd.	Quinazoline derivatives for the treatment and prevention of diabetes and obesity
DE602006020327D1 (de)	2005-01-19	2011-04-07	Bristol Myers Squibb Co	2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
DE102005025161A1 (de)	2005-06-01	2006-12-07	Phenion Gmbh & Co. Kg	Derivate des Pyrimidins und Triazins und deren Verwendung
EP1917259B1 (en) *	2005-08-18	2012-01-25	Vertex Pharmaceuticals Incorporated	Pyrazine kinase inhibitors
JPWO2007026761A1 (ja) *	2005-08-31	2009-03-12	アステラス製薬株式会社	チアゾール誘導体
WO2007038387A2 (en)	2005-09-23	2007-04-05	Yale University	Compounds and methods for the treatment of viruses and cancer
JP5137207B2 (ja)	2005-11-01	2013-02-06	アレイバイオファーマ、インコーポレイテッド	グルコキナーゼ活性化因子
WO2007056163A2 (en)	2005-11-03	2007-05-18	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
AU2006315334B2 (en)	2005-11-16	2011-05-19	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
WO2007058482A1 (en)	2005-11-16	2007-05-24	Lg Life Sciences, Ltd.	Novel inhibitors of protein kinase
JP5236499B2 (ja)	2006-01-27	2013-07-17	アレイバイオファーマ、インコーポレイテッド	グルコキナーゼ活性化剤
AU2007235558B2 (en)	2006-03-24	2011-12-01	Array Biopharma Inc.	2 -aminopyridine analogs as glucokinase activators
ES2352320T3 (es)	2006-05-12	2011-02-17	Ab Science	Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
WO2008024963A1 (en)	2006-08-24	2008-02-28	Serenex, Inc.	Benzene, pyridine, and pyridazine derivatives
CL2007003061A1 (es)	2006-10-26	2008-08-01	Astrazeneca Ab	Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
PT2091918E (pt)	2006-12-08	2014-11-24	Irm Llc	Compostos e composições como inibidores de proteína cinase
WO2008091770A1 (en)	2007-01-24	2008-07-31	Array Biopharma Inc.	2-aminopyridine derivatives as glucokinase activators
CA2681695A1 (en)	2007-03-23	2008-10-02	Array Biopharma Inc.	2-aminopyridine analogs as glucokinase activators
JP5516397B2 (ja)	2007-04-05	2014-06-11	アムジエン・インコーポレーテツド	オーロラキナーゼ調節物質及び使用方法
US20090012091A1 (en)	2007-07-02	2009-01-08	Kinagen, Inc.	Oximide derivatives and their therapeutical application
UY31281A1 (es)	2007-08-13	2009-03-31		Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
ES2569734T3 (es)	2007-09-21	2016-05-12	Array Biopharma, Inc.	Derivados de piridin-2-il-tiourea y de piridin-2-il-amina como intermedios para la preparación de piridin-2-il-amino-1,2,4-tiadiazoles activadores de la glucocinasa
PT2195312E (pt)	2007-10-09	2013-02-20	Merck Patent Gmbh	Derivados de piridina úteis como ativadores de glucocinase

2008
- 2008-09-15 ES ES13186328.4T patent/ES2569734T3/es active Active
- 2008-09-15 EA EA201000515A patent/EA019104B1/ru not_active IP Right Cessation
- 2008-09-15 EP EP13186328.4A patent/EP2727910B1/en not_active Not-in-force
- 2008-09-15 PL PL08834504T patent/PL2209778T3/pl unknown
- 2008-09-15 MX MX2010002772A patent/MX2010002772A/es active IP Right Grant
- 2008-09-15 PT PT88345046T patent/PT2209778E/pt unknown
- 2008-09-15 CN CN2008801169950A patent/CN101868459B/zh not_active Expired - Fee Related
- 2008-09-15 WO PCT/US2008/076401 patent/WO2009042435A1/en not_active Ceased
- 2008-09-15 US US12/678,995 patent/US8212045B2/en not_active Expired - Fee Related
- 2008-09-15 EP EP16160414.5A patent/EP3078662A1/en not_active Withdrawn
- 2008-09-15 KR KR1020107008594A patent/KR101566042B1/ko not_active Expired - Fee Related
- 2008-09-15 AU AU2008305294A patent/AU2008305294B2/en not_active Ceased
- 2008-09-15 JP JP2010525902A patent/JP5722037B2/ja not_active Expired - Fee Related
- 2008-09-15 DK DK08834504.6T patent/DK2209778T3/da active
- 2008-09-15 HR HRP20120814AT patent/HRP20120814T1/hr unknown
- 2008-09-15 MY MYPI2010001186A patent/MY180558A/en unknown
- 2008-09-15 NZ NZ583538A patent/NZ583538A/en not_active IP Right Cessation
- 2008-09-15 EP EP12181665A patent/EP2573087A1/en not_active Withdrawn
- 2008-09-15 UA UAA201004782A patent/UA101166C2/ru unknown
- 2008-09-15 ES ES08834504T patent/ES2393824T3/es active Active
- 2008-09-15 BR BRPI0816881 patent/BRPI0816881A2/pt not_active IP Right Cessation
- 2008-09-15 SI SI200830746T patent/SI2209778T1/sl unknown
- 2008-09-15 CA CA2699718A patent/CA2699718C/en not_active Expired - Fee Related
- 2008-09-15 EP EP08834504A patent/EP2209778B1/en not_active Not-in-force
- 2008-09-19 AR ARP080104095A patent/AR068628A1/es not_active Application Discontinuation
- 2008-09-19 TW TW097136197A patent/TWI423799B/zh not_active IP Right Cessation
2010
- 2010-03-02 IL IL204264A patent/IL204264A/en not_active IP Right Cessation
- 2010-03-04 TN TNP2010000100A patent/TN2010000100A1/fr unknown
- 2010-03-29 ZA ZA2010/02206A patent/ZA201002206B/en unknown
- 2010-04-14 MA MA32775A patent/MA31779B1/fr unknown
- 2010-04-21 CO CO10046631A patent/CO6270223A2/es not_active Application Discontinuation
- 2010-04-21 CR CR11383A patent/CR11383A/es unknown
2011
- 2011-03-29 ZA ZA2011/02350A patent/ZA201102350B/en unknown
2012
- 2012-06-11 US US13/493,616 patent/US8853409B2/en not_active Expired - Fee Related
2014
- 2014-09-23 US US14/494,430 patent/US9079890B2/en not_active Expired - Fee Related
2015
- 2015-03-12 CR CR20150131A patent/CR20150131A/es unknown

Also Published As

Publication number	Publication date
CR11383A (es)	2010-08-13
EP2727910B1 (en)	2016-03-16
US8853409B2 (en)	2014-10-07
HK1145498A1 (en)	2011-04-21
EP2209778B1 (en)	2012-08-29
JP5722037B2 (ja)	2015-05-20
MY180558A (en)	2020-12-02
UA101166C2 (ru)	2013-03-11
US20120277242A1 (en)	2012-11-01
CA2699718C (en)	2014-05-27
CN101868459B (zh)	2013-12-18
US20100204240A1 (en)	2010-08-12
HRP20120814T1 (hr)	2012-11-30
EP3078662A1 (en)	2016-10-12
EA019104B1 (ru)	2014-01-30
KR101566042B1 (ko)	2015-11-04
IL204264A (en)	2015-06-30
AU2008305294A1 (en)	2009-04-02
EP2573087A1 (en)	2013-03-27
US9079890B2 (en)	2015-07-14
AU2008305294B2 (en)	2012-11-29
NZ583538A (en)	2012-06-29
TN2010000100A1 (en)	2011-09-26
CA2699718A1 (en)	2009-04-02
AR068628A1 (es)	2009-11-25
SI2209778T1 (sl)	2012-12-31
HK1197821A1 (en)	2015-02-18
EP2727910A1 (en)	2014-05-07
US20150057448A1 (en)	2015-02-26
DK2209778T3 (da)	2012-09-17
CO6270223A2 (es)	2011-04-20
WO2009042435A8 (en)	2009-10-08
JP2010540443A (ja)	2010-12-24
TWI423799B (zh)	2014-01-21
ES2569734T3 (es)	2016-05-12
WO2009042435A1 (en)	2009-04-02
EP2209778A1 (en)	2010-07-28
KR20100080809A (ko)	2010-07-12
ES2393824T3 (es)	2012-12-28
CR20150131A (es)	2015-04-30
EA201000515A1 (ru)	2010-10-29
TW200914007A (en)	2009-04-01
PL2209778T3 (pl)	2013-02-28
CN101868459A (zh)	2010-10-20
US8212045B2 (en)	2012-07-03
ZA201102350B (en)	2012-09-26
PT2209778E (pt)	2012-12-06
ZA201002206B (en)	2011-06-29
MX2010002772A (es)	2010-03-31
MA31779B1 (fr)	2010-10-01

Publication	Publication Date	Title
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0913585A2 (pt)	2015-10-27	composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0912348A2 (pt)	2015-10-13	composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças
BRPI0917138A2 (pt)	2015-11-17	composto, métodos para tratar doenças alérgicas e outras condições inflamatórias, rinite alérgica, e para tratar ou prevenir doença, composição farmacêutica, uso de um composto, e, combinação.
BRPI0915084A2 (pt)	2015-10-27	composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0819755A2 (pt)	2018-07-17	composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0821299A2 (pt)	2015-06-16	Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0819799A2 (pt)	2015-05-26	Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0819218A2 (pt)	2015-05-05	Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0813237A2 (pt)	2014-12-23	Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0907974A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI1013396A2 (pt)	2016-03-29	composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI0906786A2 (pt)	2015-07-14	Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BRPI0816255A2 (pt)	2015-03-17	Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
BRPI0718587A2 (pt)	2014-03-11	Uso de um composto, compostos, método de tratamento ou prevenção de doenças, processos para a preparação do composto e composição farmacêutica contendo o mesmo
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
CL2007003832A1 (es)	2008-07-25	Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades.

Legal Events

Date	Code	Title	Description
2017-10-24	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-05-28	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-09	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 11A ANUIDADE.
2019-10-29	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2531 DE 09-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.